Menu

New products

Daewoong Pharma is striving to develop innovative drugs that can improve global health.
We are always welcoming for a new idea in various fields and we can work together, we can work together for global drug development.

Innovative new medicines
New biologics
Incrementally modified drugs
/ specialty generics
Drug substance
  • Indications

    Wrinkles, upper limb muscle stiffness, etc.

  • Mechanism

    Secretion-blocking of acetylcholine which is a neurotransmitter

  • Development stage

    Released in Korea (for wrinkles and upper limb muscle stiffness), Expanding indications (Phase 3 clinical trial - wrinkles, Phase 2 clinical trial – eyelid spasm), Global market (U.S. / Europe: Preparing for product approval, China: Submitted CTA application)

  • Scheduled release date

    U.S./Europe in 2018, China in 2022

  • Partnership areas

    New indications and animal models, Development of in-vitro toxin activity measuring method to replace animal evaluation, Technology related to the development of recombinant botulinum toxin, Development of products using botulinum toxin other than Type A1.

New platform technology

Daewoong Pharma is always opened to partnership in various fields.
Please take a look at the following areas for cooperation and propose your platform technologies.

Drug substance (API) production platform
  • Core competencies of Daewoong Pharma
    • Possession of advanced research system and special facilities : cGMP quality management system, facilities and equipment infrastructure
    • API manufacturing synthesis competitiveness and know-how : Developed and exported products such as valsartan, meropenem, lansoprazole, rabeprazole, and choline alfoscerate based on UDCA R&D and industrialization technology experience to developed countries
  • Partnership areas
    • Production of CA/CDCA using various sources, improvement of UDCA synthesis process
    • CDMO partnership
Ion channel platform
  • Progress status
    • Identification of candidate materials for Nav1.7 innovative pain medicine
  • Core competencies of Daewoong Pharma
    • Ion cannel evaluation technology
    • Ion channel high-through put evaluation method, patch clamp equipment/technology
    • Ion channel focused chemical libraries and 100,000 in-house compounds (TRPV1, Nav1.7 target)
    • In-vivo animal model based assessment for Neuropathic pain disorders
  • Partnership areas
    • New ion channel targets and disease studies
    • Primary cell, ex-vivo evaluation technology, ion channel established cell technology
Stem cell platform
  • Progress status
    • Clinical studies : Atopy, Cronhn’s disease, and rheumatoid arthritis
    • Investigator initiated clinical : Cerebellar atrophy, vesicular epidermolysis, and acute severe pancreatitisc
    • Efficacy evaluation in animal study : Dementia, degenerative arthritis, liver disease, and stroke
  • Core competencies of Daewoong Pharma
    • Two types of mesenchymal stem cells (ES-MSC, UCB-MSC), growth factors (EGF,EPO,hGH,BMP-2)
    • Cell treatment GMP facilities : Research facilities for evaluating and enhancing efficacy of stem cells (open to partners)
    • Systematic system for stem cell research : Latest papers and development trend information, statistical analysis
    • preparation of thesis and IRB review research plan, and IND application related affairs
  • Partnership areas
    • Finding new efficacy of stem cells, expansion of indications, stem cell efficacy enhancement technology, and mass culture technology
Escherichia coli based platform
  • Progress status
    • EGF, EPO, hGH (Growth hormone), BMP-2 products are released
    • Identification of insulin bio-better candidate materials
  • Core competencies of Daewoong Pharma
    • Activation technology and expertise suitable for the characteristics of various types of protein : Refolding, active type, secretory type, etc.
    • Approval/commercialization/production capability of Escherichia coli-based biologics : Commercialization capability of Escherichia coli-based biologics such as EGF, BMP-2, hGH, EPO
  • Partnership areas
    • Protein extended-release preparation technology, new protein drugs using new MOA (mode of action), and metabolic engineering technology to increase the production of recombinant protein
    • Protein skin permeation technology, protein room temperature stabilization technology
Depot technology platform
  • Progress
    • Long-term release anticancer drug : Nonclinical study / Nano path type dementia treatment : Clinical study / Leuprolide depot’s entry into the US market : Clinical study / Sustained-release antithrombotic preparation : Formulation study / - Long-term release dementia treatment : Formulation study
  • Core competencies of Daewoong Pharma
    • Depot injection based technology : Microsphere technology (spray type, emulsion type, nano suspension), Sustained-release preparation technology such as nano suspension technology which is applicable to poorly soluble drugs
    • Animal/preliminary clinical system capable of speedy POC evaluation
    • Luphere manufacturing competitiveness : Building Leuprolide depot cGMP plant, Dual-chamber syringe technology
  • Partnership areas
    • New substance to which depot injection technology can be applied
    • Sustained-release preparation platform technology
    • Product manufacturing CDMO (Contract Development and Manufacturing Organization)
Drug substance (API) production platform
  • Core competencies of Daewoong Pharma
    • Possession of advanced research system and special facilities : cGMP quality management system, facilities and equipment infrastructure
    • API manufacturing synthesis competitiveness and know-how : Developed and exported products such as valsartan, meropenem, lansoprazole, rabeprazole, and choline alfoscerate based on UDCA R&D and industrialization technology experience to developed countries
  • Partnership areas
    • Production of CA/CDCA using various sources, improvement of UDCA synthesis process
    • CDMO partnership
Ion channel platform
  • Progress status
    • Identification of candidate materials for Nav1.7 innovative pain medicine
  • Core competencies of Daewoong Pharma
    • Ion cannel evaluation technology
    • Ion channel high-through put evaluation method, patch clamp equipment/technology
    • Ion channel focused chemical libraries and 100,000 in-house compounds (TRPV1, Nav1.7 target)
    • In-vivo animal model based assessment for Neuropathic pain disorders
  • Partnership areas
    • New ion channel targets and disease studies
    • Primary cell, ex-vivo evaluation technology, ion channel established cell technology
next previous